Balance between activation and inhibition of matrix metalloproteinase-2 (MMP-2) is altered in colorectal tumors compared to normal colonic epithelium

Digestive Diseases and Sciences

Volumn 47, Issue 8, 2002, Pages 1821-1830

  Ornstein, Deborah L ^a   Cohn, Kenneth H ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b VA MEDICAL CENTER   (United States)

Author keywords

Colorectal cancer; Malignant transformation; Matrix metalloproteinases; Metastasis

Indexed keywords

GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER TISSUE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLON MUCOSA; COLORECTAL TUMOR; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; METASTASIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

COLON; COLORECTAL NEOPLASMS; ENZYME ACTIVATION; EPITHELIUM; HUMANS; INTESTINAL MUCOSA; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; POLYMERASE CHAIN REACTION; RNA; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 0036335812     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016456914723     Document Type: Article

References (76)

1. Tumor invasion and metastasis: An imbalance of positive and negative regulation
2. Laminin expression in colorectal carcinomas varying in degree of differentiation
3. Tumour basement membrane laminin in adenocarcinoma of rectum: An immunohistochemical study of biological and clinical significance
4. Loss of basement membrane components by invasive tumors but not by their benign counterparts
5. Matrix metalloproteinases and metastasis
6. Proteolysis in human breast and colorectal cancer
7. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours
8. Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma
9. Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression
10. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy
11. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas
12. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis
13. Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice
14. Metastasis of human colon tumor cells in vivo: Correlation with the overexpression of plasminogen activators and 72 kDa gelatinase
15. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples
16. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer
17. Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors
18. Changing views of the role of matrix metalloproteinases in metastasis
19. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
20. Correlation between expression of matrix metalloproteinase-2 (MMP-2), and matrix metalloproteinase-9 (MMP-9) and angiogenesis in colorectal adenocarcinoma
21. A matrix metalloproteinase expressed on the surface of invasive tumour cells
22. Membrane-type matrix metalloproteinases (MT-MMPs) in cell invasion
23. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study
24. Dual over-expression pattern of membrane-type metalloproteinase- 1 in cancer and stromal cells in human gastrointestinal carcinoma revealed by in situ hybridization and immunoelectron microscopy
25. Membrane-type 1 matrix metalloproteinase mRNA expression in colorectal cancer
26. Proteases and protease inhibitors in tumor progression
27. Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface
28. Reversal of misfortune: TIMP-2 inhibits tumor cell invasion
29. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma
30. Augmented membrane type 1 matrix metalloproteinase (MT1-MMP): MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis
31. Correlation of the in situ detection of polymerase chain reactionamplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma
32. Determination of imbalance between-MMP-2 and TIMP-2 in human neuroblastoma by reverse-transcription polymerase chain reaction and its correlation with tumor progression
33. Analysis of cytokine mRNA and DNA: Detection and quantitation by competitive polymerase chain reaction
34. Rapid generation of internal standards for competitive PCR by low-stringency primer annealing
35. The significance of allelic deletions and aneuploidy in colorectal carcinoma: Results of a 5-year follow-up study
36. Expression pattern of metalloproteinases and their inhibitors changes with the progression of human sporadic colorectal neoplasia
37. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis
38. Proteolysis in colorectal cancer
39. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 an dBM-40/SPARC genes
40. Prognostic value of plasminogen activators and their inhibitors in colorectal cancer
41. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia
42. Enhanced secretion and activation of matrilysin during malignant conversion of human colorectal epithelium and its relationship with invasive potential of colon cancer cells
43. Matrilysin in early stage intestinal tumorigenesis
44. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer
45. Gelatinase A (MMP-2) and its mRNA detected in both neoplastic and stromal cells of tumors with different invasive and metastatic properties
46. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas
47. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer-a predictor of tumour stage
48. Metastatic colorectal cancer cells induce matrix metalloproteinase release by human monocytes
49. Evidence for tumor-host cooperation in regulating MMP-2 expression in human colon cancer
50. Activation of fibroblast-derived matrix metalloproteinase-2 by colon-cancer cells in non-contact co-cultures
51. Metastatic and non-metastatic colorectal (CRC) induce host metalloproteinase production in vivo
52. Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer
53. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer
54. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer
55. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9
56. Clinicopathologic significance of urokinase receptorand MMP-9-positive stromal cells in human colorectal cancer: Functional multiplicity of matrix degradation on hematogenous metastasis
57. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases
58. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer
59. Host expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in normal colon tissue affects metastatic potential of colorectal cancer
60. Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat
61. Recent advances in matrix metalloproteinase inhibitors research
62. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models
63. Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats
64. Correlation of antangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor
65. Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor
66. Marimastat (BB2516): Current status of development
67. A randomized double-blind Placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma
68. Protracted daily treatment with Col-3, an oral tetracycline analog, matrix metalloproteinase (MMP) inhibitor, is feasible: A phase I, pharmacokinetic and biological study
69. Phase I/pharmacokinetic study of the metalloproteinase and angiogenesis inhibitor Bayer 12-9566 (BAY) in conjunction with 5-fluorouracil/folinic acid (FU/FA)
70. Phase I study of the matrix metalloprotease inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients With advanced solid tumors
71. A novel approach to studying the efficacy of AG3340, a selective inhibitor of matrix metalloproteases (MMPS)
72. Matrix metalloproteinase inhibitors: Applications in oncology
73. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
74. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
75. Cydooxygenase-2 expression in human colon cancer cells increases metastatic potential
76. Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2